IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1201-1225 out of 1315.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

Public Release: 10-Dec-2014
Science Translational Medicine
Targeting mitochondrial enzyme may reduce chemotherapy drug's cardiac side effects
Massachusetts General Hospital investigators have identified two compounds that appear, in cellular and animal models, to block the cardiac damage caused by the important chemotherapy drug doxorubicin without reducing its anti-tumor effects.
American Heart Association

Contact: Cassandra Aviles
Massachusetts General Hospital

Public Release: 10-Dec-2014
Many breast cancer surgery patients do not receive shorter radiation treatment
Although the use of a type of radiation treatment that is shorter in duration and less costly has increased among women with early-stage breast cancer who had breast conserving surgery, most patients who meet guidelines to receive this treatment do not, according to a study appearing in JAMA. The study is being released to coincide with the San Antonio Breast Cancer Symposium.

Contact: Steve Graff
The JAMA Network Journals

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker -- the quantity of tumor-infiltrating lymphocytes in a biopsy -- appears irrelevant when trastuzumab is used.
Mayo Clinic, Donna Foundation, Breast Cancer Research Foundation, NIH/National Cancer Institute, Alliance for Clinical Trials in Oncology, North Central Cancer Treatment Group

Contact: Paul Scotti
Mayo Clinic

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Novel approach for estrogen-receptor-positive breast cancer reported
Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

Contact: Nora Dudley
Loyola University Health System

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Early trial of new drug shows promise for patients with triple-negative breast cancer
In patients with metastatic triple-negative breast cancer, infusion of pembrolizumab produced durable responses in almost one out of five patients. One of the 27 patients had a complete response and four had a partial response. Seven more patients had stable disease.

Contact: John Easton
University of Chicago Medical Center

Public Release: 10-Dec-2014
Most women with early-stage breast cancer in US receive radiation for too long
Two-thirds of women treated for early-stage breast cancer in the US receive longer radiation therapy than necessary, according to a new study published in JAMA this week from Penn Medicine researchers Ezekiel J. Emanuel, M.D., Ph.D., and Justin E. Bekelman, M.D.
Anthem, Inc., NIH/National Cancer Institute

Contact: Steve Graff
University of Pennsylvania School of Medicine

Public Release: 10-Dec-2014
Molecular Oncology
New breast cancer classification based on epigenetics
Breast cancer is the most common in women. One in nine will suffer breast cancer over their lifetime. Progress in prevention and early detection, and the use of chemotherapy after surgery (adjuvant chemotherapy), have achieved significantly increase survival in this disease in the last ten years, but much remains to be done.
Icelandic Centre for Research, CellexFoundation

Contact: Arantxa Mena
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
German breast group study: Superior activity for nab-paclitaxel in early breast cancer
German Breast Group Ph III study demonstrates superior activity for nab-paclitxel vs conventional paclitaxel in early, high-risk breast cancer, and utility of pCR (pathological complete response) as a surrogate marker for long-term efficacy

Contact: Peggy C. Frank
Initiate PR

Public Release: 10-Dec-2014
Chemical Research in Toxicology
New technology tracks carcinogens as they move through the body
Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.
Public Health Service, US Department of Energy, NIH/National Institute of General Medical Sciences

Contact: David Williams
Oregon State University

Public Release: 10-Dec-2014
Molecular tag team revealed to control cell division
Manchester scientists have explored the role of three molecules in controlling the process of cell division in a bid to gain new insight into the transmission of vital signals from a cell's exterior to its interior.
Cancer Research UK

Contact: Jamie Brown
University of Manchester

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
New drug combination for advanced breast cancer delays disease progression
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven.
NIH/National Cancer Institute, Millenium, Takeda Oncology Company

Contact: Vicky Agnew
Yale University

Public Release: 10-Dec-2014
Journal of Cardiac Failure
NYIT study: Thyroid hormones reduce animal cardiac arrhythmias
Rats that received thyroid hormones had a reduced risk for dangerous heart arrhythmias following a heart attack, according to a new study by a team of medical researchers at New York Institute of Technology. In the National Institutes of Health-funded study, published in the Journal of Cardiac Failure, the team found that thyroid hormone replacement therapy significantly reduced the incidence of atrial fibrillation -- a specific kind of irregular heartbeat, or arrhythmia -- in the rats, compared to a control group that did not receive the hormones.
National Institutes of Health

Contact: Elaine Iandoli
New York Institute of Technology

Public Release: 10-Dec-2014
Nature Communications
New insight into cancer defense mechanism
Researchers at the University of Copenhagen have identified a new mechanism which gives a better understanding of cancer development. The results have just been published in the scientific journal Nature Communications.

Contact: Jakob Nilsson
University of Copenhagen - The Faculty of Health and Medical Sciences

Public Release: 10-Dec-2014
San Antonio Breast Cancer Symposium
Pathway that degrades holiday turkey fuels metastasis of triple negative breast cancer
A University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.

Contact: Garth Sundem
University of Colorado Denver

Public Release: 10-Dec-2014
Proceedings of the National Academy of Sciences
Testosterone may contribute to colon cancer tumor growth
James Amos-Landgraf, an assistant professor of veterinary pathobiology in the MU College of Veterinary Medicine, found evidence suggesting that the male hormone testosterone may actually be a contributing factor in the formation of colon cancer tumors.
National Institutes of Health, American Cancer Society

Contact: Nathan Hurst
University of Missouri-Columbia

Public Release: 9-Dec-2014
Journal of Nuclear Medicine
Nuclear medicine treatment shows promise for cancer therapy
Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

Contact: Kimberly Brown
Society of Nuclear Medicine

Public Release: 9-Dec-2014
Annals of Epidemiology
Smoking still causes large proportion of cancer deaths in the United States
A new American Cancer Society study finds that despite significant drops in smoking rates, cigarettes continue to cause about three in ten cancer deaths in the United States.
NIH/National Cancer Institute, American Cancer Society

Contact: David Sampson
American Cancer Society

Public Release: 9-Dec-2014
Metal test could help diagnose breast cancer early
It may be possible to develop a simple blood test that, by detecting changes in the zinc in our bodies, could help to diagnose breast cancer early.

Contact: University of Oxford News Office
University of Oxford

Public Release: 9-Dec-2014
International Journal of Radiation Oncology • Biology • Physics
Analysis shows increased use of HF-WBI for patients with early-stage breast cancer
The use of hypofractionated whole-breast irradiation for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive hypofractionated whole-breast irradiation compared to conventionally fractionated whole-breast irradiation when they are treated at an academic center or live less than or equal to 50 miles away from a cancer center, according to a study published in the Dec. 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics.

Contact: Michelle Kirkwood
American Society for Radiation Oncology

Public Release: 9-Dec-2014
2014 San Antonio Breast Cancer Symposium
Three new Myriad studies highlighted at 2014 San Antonio Breast Cancer Symposium
Three new Myriad studies presented at the 2014 San Antonio Breast Cancer Symposium found that the myRisk Hereditary Cancer test detected 105 percent more mutations in cancer causing genes than conventional BRCA testing alone; the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage triple negative breast cancer and the BRACAnalysis test significantly predicted response to platinum-based drugs in patients with metastatic triple negative breast cancer.

Contact: Ronald Rogers
Myriad Genetics, Inc.

Public Release: 9-Dec-2014
Nicotine & Tobacco Research
E-cigarettes less addictive than cigarettes
E-cigarettes appear to be less addictive than cigarettes for former smokers and this could help improve understanding of how various nicotine delivery devices lead to dependence, according to researchers.
NIH/National Institute on Drug Abuse, US Food and Drug Administration

Contact: Matt Solovey
Penn State

Public Release: 9-Dec-2014
Annals of Internal Medicine
Women with dense breasts will have to look beyond ultrasound for breast cancer screening
Supplemental ultrasound screening for all US women with dense breasts would substantially increase healthcare costs with little improvement in overall health, according to a Dartmouth-led research study.
NIH/National Cancer Institute

Contact: Kirk Cassels
The Geisel School of Medicine at Dartmouth

Public Release: 9-Dec-2014
Journal of National Cancer Institute
Mayo Clinic: Genotyping errors plague CYP2D6 testing for tamoxifen therapy
Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of a Mayo Clinic study published in the Journal of the National Cancer Institute.
National Institutes of Health, Mayo Clinic, Breast Cancer Research Foundation

Contact: Joe Dangor
Mayo Clinic

Public Release: 9-Dec-2014
2014 San Antonio Breast Cancer Symposium
James Ingle of Mayo Clinic Recognized for Breast Cancer Research
James Ingle, M.D., an internationally recognized breast cancer expert, will receive the 2014 William L. McGuire Memorial Lecture Award on Dec. 10 at the 2014 San Antonio Breast Cancer Symposium.

Contact: Joe Dangor
Mayo Clinic

Public Release: 9-Dec-2014
Annals of Otology, Rhinology & Laryngology
Long-term results confirm success of MGH-developed laser treatment for vocal-cord cancer
The first long-term study of a pioneering endoscopic laser treatment for early vocal-cord cancer, developed at Massachusetts General Hospital and previously shown to provide optimal voice outcomes, finds that it is as successful as traditional approaches in curing patients' tumors while avoiding the damage to vocal quality caused by radiotherapy or by conventional laser or cold-instrument surgery.
National Philanthropic Trust, 'V' Foundation, Eugene B. Casey Foundation, Voice Health Institute

Contact: Mike Morrison
Massachusetts General Hospital

Showing releases 1201-1225 out of 1315.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

  Search News Releases